OS Therapies Reports Positive Clinical Trial Outcome
Shares of OS Therapies, Inc. (NYSE-A: OSTX) experienced a remarkable 58% increase following their announcement regarding the successful Phase 2b clinical trial results for their immunotherapy candidate, OST-HER2. This innovative therapy aims to prevent recurrent lung metastatic osteosarcoma, a rare and challenging cancer.
Impact of the Trial Results
The clinical-stage biotechnology company, based in New York, has demonstrated that the trial met its primary endpoint with notable statistical significance. Patients treated with OST-HER2 achieved a 12-month Event Free Survival (EFS) rate of 33.3%. In contrast, the historical control group reported only a 20% rate, with a p-value of 0.0158. This notable enhancement in EFS indicates a meaningful advancement for patients battling this rare illness, highlighting the treatment's potential in a market currently void of approved therapies.
Secondary Endpoint Analysis
Interim analyses regarding the secondary endpoint of 3-year overall survival (OS) have also indicated a positive trend for patients undergoing OST-HER2 treatment at both the 1-year and 2-year marks. Remarkably, all patients reaching the 12-month EFS milestone remain alive, emphasizing the therapy's efficacy. Furthermore, the safety profile of OST-HER2 was well-regarded, with reports showcasing that the treatment was generally well-tolerated by participants during the study.
Insights from Company Leadership
Dr. Robert Petit, the Chief Medical and Scientific Officer, shared his enthusiasm regarding the trial's findings, pointing out the significant increase in the likelihood of survival at both the 1-year and 2-year intervals when compared to historical controls. Paul Romness, the Chair & CEO of OS Therapies, highlighted the company's commitment to pursuing an accelerated approval pathway with the U.S. FDA for OST-HER2, a crucial step forward for the company.
Details of the Phase 2b Study Design
The Phase 2b study consisted of 39 evaluable patients from 21 centers. Patients aged between 12 and 39 years with a history of recurrent, fully resected lung metastatic osteosarcoma were accepted into the study and received the investigational OST-HER2 treatment. The structure of the trial involved a study duration of 52 weeks, with participants undergoing 16 doses of the therapy every three weeks for 48 weeks, culminating in a 4-week final visit for evaluation.
Market Reaction to Trial Success
The encouraging results from the trial have evidently resonated well with the investor community. OSTX stocks have surged as the market eagerly responds to the potential for OST-HER2 to emerge as the first approved treatment for lung metastatic osteosarcoma. The company's commitment to addressing the unmet therapeutic needs for patients suffering from rare cancers continues to stand at the forefront of their clinical and regulatory strategies.
Frequently Asked Questions
What did the recent trial for OST-HER2 indicate?
The trial for OST-HER2 showed a statistically significant 12-month Event Free Survival rate of 33.3%, indicating its potential effectiveness.
How did the stock of OS Therapies react to the trial results?
Upon the announcement of trial success, shares of OS Therapies rose by 58% as investors responded positively to the news.
What does EFS mean in medical trials?
EFS stands for Event Free Survival, which measures the time post-treatment during which a patient does not experience any recurrence of cancer.
What is the age range of patients involved in the Phase 2b study?
The Phase 2b study included patients aged between 12 and 39 years who had lung metastatic osteosarcoma.
What are the next steps for OS Therapies after the trial results?
OS Therapies intends to pursue an accelerated approval pathway with the U.S. FDA for OST-HER2 based on the successful trial results.
